Skip to main content
. 2021 May 21;11(5):101. doi: 10.1038/s41408-021-00490-8

Table 5.

Treatment exposure in the safety population.

C-Rd Group (n = 143) Control Group (n = 143)
Median duration of study treatment—mo (range) 15 (0.2–44) 15.9 (0.4–46)
Median total number of cycles received—no. (range) 10 (1–48) 14 (1–47)
Median relative dose intensity—% (range)
 Clarithromycin 80 (35.7–98.4)
 Lenalidomide 72.1 (0–98.6) 83.3 (19–97.0)
 Dexamethasone 62.8 (0–71.4) 84.3 (0–88.7)